Integra LifeSciences (IART) Institutional Ownership

84.78% of Integra LifeSciences' stock is owned by institutional investors. Learn more on IART's institutional investor holdings.

Of the 170 institutional investors that purchased Integra LifeSciences' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Paradigm Capital Management Inc. NY ($6.62M), Rubric Capital Management LP ($3.40M), Sachem Head Capital Management LP ($2.43M), Assenagon Asset Management S.A. ($1.80M), Soleus Capital Management L.P. ($1.59M), Access Investment Management LLC ($898.67K), and Systematic Financial Management LP ($707.54K).

Institutional investors have bought a total of 13,505,660 shares in the last 24 months. This purchase volume represents approximately $185.76M in transactions.

Of the 72 institutional investors that sold Integra LifeSciences' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Deerfield Management Company L.P. ($174.36M), Invesco Ltd. ($50.22M), JPMorgan Chase & Co. ($14.53M), Millennium Management LLC ($5.69M), UBS Group AG ($4.71M), Assenagon Asset Management S.A. ($1.13M), and Fuller & Thaler Asset Management Inc. ($556.16K).

Institutional investors have sold a total of 255,348,415 shares in the last 24 months. This volume of shares sold represents approximately $3.65B in transactions.